Elderly Patients with Acute Coronary Syndromes Managed Without Revascularization Insights into the Safety of Long-Term Dual Antiplatelet Therapy with Reduced-Dose Prasugrel vs. Standard-Dose Clopidogrel

Matthew T Roe, Shaun G Goodman, E Magnus Ohman, Susanna R Stevens, Judith S Hochman, Shmuel Gottlieb, Felipe Martinez, Anthony J Dalby, William E Boden, Harvey D White, Dorairaj Prabhakaran, Kenneth J Winters, Philip E Aylward, Jean-Pierre Bassand, Darren K McGuire, Diego Ardissino, Keith A A Fox, Paul W Armstrong

Research output: Contribution to journalArticlepeer-review

Abstract

Dual antiplatelet therapy in older vs. younger patients with acute coronary syndromes (ACS) is under-studied. Low-dose prasugrel (5mg/d) is recommended for younger, lower-body-weight ACS patients and elderly ACS patients to mitigate bleeding risk of standard-dose prasugrel (10mg/d).
Original languageEnglish
JournalCirculation
DOIs
Publication statusPublished - 12 Jul 2013

Keywords

  • Aging
  • Drug therapy
  • Fibrinolytic Agents
  • Myocardial Infarction
  • RECEPTORS
  • purinergic P2Y12

Fingerprint

Dive into the research topics of 'Elderly Patients with Acute Coronary Syndromes Managed Without Revascularization Insights into the Safety of Long-Term Dual Antiplatelet Therapy with Reduced-Dose Prasugrel vs. Standard-Dose Clopidogrel'. Together they form a unique fingerprint.

Cite this